Solventum Corporation (SOLV)

Solventum reported its fourth-quarter 2025 earnings on February 26, 2026, and its first-quarter 2026 earnings on May 5, 2026. Solventum participated in several investor conferences and issued a year-end 2025 shareholder letter on December 16, 2025. The company has been integrating the Acera acquisition and making substantial progress on its ERP migration. Solventum commenced executing a $1 billion share repurchase plan. As of May 8, 2026, Solventum's stock was trading at $73.40 and has decreased by 7.5% since the start of 2026.

Solventum's business experiences demand seasonality. The company has noted "typical first quarter seasonality" and "normal manufacturing seasonality" in relation to its gross margins and cash flow. Certain quarters may historically see fluctuations in demand, production, and associated financial metrics.

Solventum's business is organized into three main segments: MedSurg, which focuses on advanced wound care, infection prevention, and surgical solutions; Dental Solutions, which provides a comprehensive suite of dental and orthodontic products; and Health Information Systems (HIS), which delivers AI-powered software solutions for clinical documentation, autonomous coding, revenue cycle management, and performance management. Solventum also retains a drinking water business and manages supply agreements related to legacy 3M businesses.

Solventum has a significant global presence with over 300 offices and facilities worldwide. While the United States accounts for the majority of its revenue, the company operates internationally, serving customers efficiently in regions including Latin America (LATAM), Europe, the Middle East and Africa (EMEA), and Asia.

Solventum's brand reputation in the past year has been shaped by its emergence as an independent entity and its efforts to establish a distinct identity from its former parent, 3M. The company is actively working to remove the 3M logo from thousands of products. The company's focus on innovation, customer satisfaction, and ethical practices aims to build a strong independent brand.

Solventum Corporation's ownership is largely characterized by a broad base of institutional investors. As of May 1, 2026, Solventum had 929 institutional owners and shareholders holding a total of 125,769,381 shares. Co 3m is noted as the largest individual Solventum shareholder, owning 25.57 million shares, representing 14.74% of the company.